Background: Severe polycythemia in the neonate may produce symptoms due to hyperviscosity and may be associated with serious complications. Partial Exchange Transfusion will reduce the haematocrit.
Introduction
Polycythemia occurs in 2-5% of term newborn 1 , usually occurring as a compensatory mechanism secondary to intrauterine fetal hypoxia, or sometimes as a result of delayed cord clamping 2 . Polycythemia leads to hyperviscosity, which can result in impaired end organ perfusion; this can manifest as neurological 3 , cardiorespiratory 4 , gastrointestinal 5 , and metabolic 6 symptoms. These symptoms are generally transient and may be minor despite severe degrees of polycythemia 7 . Although serious complications such as renal vein thrombosis or cerebral venous sinus thrombosis have been described in infants with polycythemia 8 , these are rare, and the principle clinical concern is that polycythemia may be associated with adverse long-term neurological sequelae.
Partial exchange transfusion (PET) has been used as a therapeutic modality to reduce Hct and thereby blood viscosity while at the same time maintaining intravascular volume 9 . Observational studies suggest that symptomatic infants who undergo PET may have an improvement in symptoms; however, the symptoms are in any case transient. More importantly, it is also unclear if PET is associated with improved long-term neurological outcome. The objective of this systematic review was to assess the efficacy and safety of PET in the treatment of the polycythemic newborn.
Methods
Criteria for inclusion Studies were included if they were randomised or quasi-randomized clinical trials; if the participants were newborns with documented central polycythemia, defined as a central haematocrit greater than or equal to 64 %; and if the interventions consisted of a PET designed to reduce central Hct to 60% or less, compared to observation only.
Outcome measures 1.
Long term neurodevelopmental, expressed as the proportion of infants with a neurologic diagnosis, proportion with developmental delay and/or with motor abnormalities at 18months or greater. Alternatively, evaluation of cognitive or motor development using a validated continuous scale was acceptable.
2.
Short term clinical neurological assessed by neurological and behavioural assessment scores 3.
Short term clinical as determined by resolution of symptoms attributed to polycythemia. 4.
Adverse events.
Search strategy for identification of studies The search was performed using the MEDLINE (1966 -2005) , EMBASE (1986 EMBASE ( -2005 and the Cochrane Register of Controlled Trials. Keywords used were; polycythemia, partial exchange transfusion, hyperviscosity and limited to newborn. Abstracts from the Society for Pediatric Research were also reviewed. The search revealed 94 reports: each was inspected to determine their suitability for inclusion. Original papers were retrieved and reviewed. Citations from these papers were also assessed.
Each identified trial was assessed for methodological quality with respect to (i) clear statement of inclusion and exclusion criteria (ii) reliability of the method of randomization including generation of randomisation sequence and masking of allocation (iii) masking of treatment groups at follow up (iv) completeness of follow up. We felt that masking of the intervention was not feasible. Where deemed appropriate metaanalysis was performed using Revman 4.2 software utilising a random effects model. For dichotomous outcomes we calculated a relative risk and 95% confidence intervals, and for continuous variables a weighted mean difference and 95% confidence interval. Heterogeneity was evaluated using the I 2 statistic.
Results
We identified a total of five randomized controlled trials of PET in newborns with polycythemia or hyperviscosity (Van der Eelst 10 , Goldberg
11
, Black 12 , Bada 13 and Ratrisawadi 14 ). A sixth study, published in abstract form by Hakanson 15 was excluded due to inadequate data availability. Table 1 provides a description of the included studies and Table2 the methodological quality of each study.
Analysis of outcomes
Neurodevelopmental Assessment at 18 months or greater Mental delay was assessed in 2 studies 12, 13 . Bada 13 presents both the mean scores and the number with "suspect/borderline mental retardation", (precise definition is not given). Black 12 presents the proportion of infants with "mental delay" (not further defined). The summary estimate of the RR for the presence of developmental delay was 1.26 (95% CI 0.62, 2.56) see figure1. Ratrisawadi's 14 quasi randomized study had only 38% follow up at 2 years, abnormal DQ (Developmental Quotient) was defined as less than 100 on the Gasel [sic] developmental test, present in 11/25 of infants treated with PET and 4/15 controls. This study had a lower quality assessment (based on method of allocation and low follow up rate). However, performing a sensitivity analysis including this study does not change the conclusion of no benefit on proportion with neurodevelopmental delay at ≥ 18 months (RR 1.36, 95% CI 0.78 2.41). At 7 years of age there was no difference between the groups in terms of IQ or scores on the Wide range achievement test 16 .
The mean difference (95% CI) for Mental Developmental Index (MDI) in the Bada 13 study was -3.0 (-12.67, 6.67). The presence of a neurological diagnosis was assessed in 2 studies 12, 13 ; the summary estimate of the RR is 0 .73 (95% CI 0.13-4.18) see figure 2. There is moderate heterogeneity for this outcome, I 2 = 40.5%.
Short term neurobehavioural assessment. Three studies 10, 11, 12 present data on short term neurobehavioural outcome assessed by the Brazelton Neonatal Behaviour Assessment Scale (BNBAS) and the Prechtl Scale. Van der Elst 10 found no difference between exchanged and observed groups in BNBAS and Prechtl scores at 10 days. Goldberg 11 found a significant decrease in abnormalities initially present on BNBAS assessment when re-examined at 2 weeks only in the exchanged patients. Black mentioned that BNBAS was performed but no data are presented. These studies do not allow us to make any firm conclusions as to the shortterm neurobehavioural effects of PET.
Short-term symptoms
The majority of infants in these studies are asymptomatic. Van der Elst 10 presents data on clinical signs and noted that peripheral cyanosis improved in all 6 patients, 5 following PET and one spontaneously in the observation group. Bada 13 noted clinical manifestations in the symptomatic polycythemic group resolved (87%) or became less severe (13%) after PET and Black 12 noted that GI symptoms were common after PET. There is inadequate firm data to reach a conclusion. 
Discussion
The current standard neonatal practice for performing a PET is (i) symptomatic with a Hct of 65% or more 17 (ii) asymptomatic with a haematocrit of 70% or more. The Committee of the Fetus and Newborn of the American Academy of Pediatrics do not issue any definitive guidelines; stating that the accepted treatment of polycythemia is PET 18 . We identified five randomized trials of PET in polycythemic newborns. Each study has small numbers of patients, utilise variable definitions of polycythemia based on Hct and have variable follow up times. Only two studies evaluated the efficacy of partial exchange in studies limited to asymptomatic patients 13, 14 ; both utilising a haematocrit of 65% or more.
There are no randomized trials of PET in only symptomatic patients, which reduces the power of this review to determine the effects of PET in such infants. This lack of information is not surprising as there is a tendency to treat all symptomatic patients with PET, probably because of published recommendations 17 . However, there appears to be no clear evidence that the long-term outcome of polycythemic infants is worse in symptomatic patients, compared to those who were asymptomatic. Bada 13 evaluated the long term outcome of the 10 non-randomized symptomatic infants in her study, which do not appear to be substantially different to the outcomes of the asymptomatic infants in the randomized trial, the Bayley MDI for example was almost identical (90 +/-13 in the symptomatic infants compared to 85 +/-9 in the PET group and 88 +/-13 in the controls). Observational studies suggest that symptoms attributed to polycythemia do improve following PET 19, 20 but these are in any case transient and the lack of controls prevents us from drawing any firm conclusions concerning the effect of PET on timing of resolution of symptoms. None of those studies that included both symptomatic and asymptomatic infants provided long term follow up information based on symptomatology. In particular patients with severe neurologic symptomatology (such as seizures) have not been reported separately, thus a possibility remains that such infants could have a long-term benefit. This, however, has not been demonstrated, highlighting the fact that there is no reliable evidence to support current practice.
The study by Bada 13 of asymptomatic infants assessed at 24months or greater was unable to show any effect of PET on longterm neurodevelopmental outcome. We combined the findings of this study with the much larger study of Black 12 (including both symptomatic and asymptomatic infants) and still found no neurological benefit. Even follow up to 7 years did not reveal any significant differences between the groups. These data would seem to indicate that probably the cause of the impaired long-term outcome is the cause of the polycythemia, most commonly intrauterine fetal hypoxia. Bada, for example, was unable to find an effect of PET, but noted on multiple regression analysis that fetal distress, hypoglycaemia and maternal pre-eclampsia were associated with poor outcome.
Although not a planned part of our analysis, data on medium term outcomes (8 months of age) were recorded in two studies 10, 11 . Van der Elst 10 reported that all infants followed to 8 months were neurologically normal and had "a developmental score appropriate for their age". Goldberg 11 examined 10 PET treated and 6 control infants and found 5/10 compared to 4/6 had abnormal neurological findings and almost identical Bayley scores. These studies included symptomatic and asymptomatic infants. Although developmental testing at such an early age does not accurately predict later functioning, these results support the findings of the planned analyses that no clinically important advantage is gained from PET.
PET is not without complications; in the 2 studies that report NEC, 9/67 PET infants, compared with 0/75 controls developed this disorder. In both studies PET was performed via umbilical catheterisation. These data suggest a temporal and causative relationship between NEC and umbilical PET. Thus the only apparent effect of PET from our analysis is an adverse outcome; however, many of the studies did not report the incidence of NEC, and the confidence intervals for this effect are very wide.
In conclusion we could not find reliable evidence that there is a clinically important benefit from PET in infants with polycythemia. There is, specifically, no evidence of a long term neurological benefit. Although the outcome of polycythemic infants is poorer than that of concurrently enrolled infants without polycythemia 11, 13 , this is most likely related to the underlying cause of polycythemia, and is not improved by PET. It remains possible that infants with severe neurological symptoms could benefit from PET, as the literature does not appear to have enough power to eliminate such a benefit, however for infants with no symptoms or only minor symptoms, such as the majority of infants enrolled in these studies, the clinical decision of whether to intervene with PET should take into account the lack of demonstrated benefit and the apparent increase in necrotizing enterocolitis. Dr. EM Dempsey is funded by McGill University, Dept of Pediatrics, Clinical/Research Fellowship in Academic Pediatrics.
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Figure 2
Forest plot of effect of partial exchange transfusion in polycythaemic newborn infants on the proportion of infants with a neurological diagnosis at 24 to 30 months of age. 
